Paradigm Biocapital Advisors LP Olema Pharmaceuticals, Inc. Call Options Transaction History
Paradigm Biocapital Advisors LP
- $2.77 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding OLMA
# of Institutions
152Shares Held
60.3MCall Options Held
141KPut Options Held
23.1K-
Bvf Inc San Francisco, CA9.14MShares$44.1 Million3.47% of portfolio
-
Bain Capital Life Sciences Investors, LLC Boston, MA7.47MShares$36.1 Million11.76% of portfolio
-
Black Rock Inc. New York, NY4MShares$19.3 Million0.0% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct3.69MShares$17.8 Million0.12% of portfolio
-
Deep Track Capital, LP Greenwich, CT3.44MShares$16.6 Million0.88% of portfolio
About Olema Pharmaceuticals, Inc.
- Ticker OLMA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 40,419,600
- Market Cap $195M
- Description
- Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, local...